Results of the Viaskin Peanut Phase III clinical trial (PEPITES), the first-ever trial for peanut allergy immunotherapy, were published in the in the Journal of American Medical Association (JAMA) on Friday.
Results showed that Viaskin Peanut, under development by French company DBV Technologies (Euronext: DBV), provided clinically meaningful desensitization in peanut-allergic children ages 4 to 11.
Peanut allergy is one of the most common food allergies and can cause a potentially life-threatening reaction. However, there has been no significant innovation in food allergy immunotherapy in the last several decades – leaving patients with avoidance as their only option.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze